Welcome : Guest

Regulus Therapeutics, Inc. (USA) - Facts, Figures and Analytical Insights

Abstract

This report presents quick facts about Regulus Therapeutics, Inc., which is principally involved in Biopharmaceuticals Business. Illustrated with 85 tables, the report showcases the company's recent news stories and events, sales performance, key markets and market position as against its competitors operating in the industry.

Code: PCP-65259
Price: $3500
Company Type: Public
Pages: 88
Date: November 2016
Market Data Tables: 85

 NOTE : Select the checkbox below, and click Add to Cart button to add this report to your shopping cart.
Table 1: Regulus Therapeutics, Inc.’s Sales by Customer (2015) in Percentage for AstraZeneca, Sanofi, and Biogen......3
Table 2: Regulus Therapeutics, Inc.'s Sales by Customer (2014) in Percentage for Sanofi, AstraZeneca, GSK, Biogen Idec and Others......4
Biopharmaceuticals......5
Table 3: Biopharmaceuticals Market by Segment Worldwide (2015) - Percentage Share Breakdown by Value for Norditropin, NovoSeven, Turoctocog Alpha, and Others......5
Cancer......6
Table 4: Oncology/Hematology Drugs Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Blood Cell Factors, Chemopreventatives, Chemotherapeutics, Mabs, Targeted Therapies, and Others......6
Table 5: Cancer Care Expenditure by Site Worldwide (2015) - Percentage Share Breakdown for Breast, Colorectal, Lymphoma, Lung, Prostate and Others......7
Table 6: Cancer Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Heme, Lung, Prostate, and Others......8
Table 7: Oncology Market by Cancer Type Worldwide (2015) - Percentage Share Breakdown by Value for Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, and Others......9
Table 8: Clinical Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......10
Table 9: Hereditary Oncology Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for US, and Others......11
Table 10: Cancer Market by Type in China (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Esophagus, Liver, Lung, Stomach and Others......12
Table 11: Oncology Market by Category in China (2015) - Percentage Share Breakdown by Value for Anti- Tumor Agents, Hormone Therapy, Immuno Suppresants and Immunostimulants......13
Table 12: Number of Cancer Patients by Type Worldwide (2015) - Percentage Share Breakdown by Volume for Bladder, Breast, Cervix Uteri, Colorectum, Liver, Lung, Non-Hodgkin lymphoma, Oesophagus, Prostate, and Stomach......14
Table 13: New Patients with Cancer by Site in the US (2015) - Percentage Market Share Breakdown by volume for Colorectal, Lung and Bronchus, Melanoma, Pancreas, and Others......15
Table 14: Number of Cancer Patients by Type in the US (2015) - Percentage Share Breakdown by Volume for Bladder Cancer, Breast Cancer (Female), Colon and Rectum Cancer, Endometrial Cancer, Kidney and Renal Pelvis Cancer, Lung and Bronchus Cancer, Melanoma of the Skin, Non-Hodgkin Lymphoma, Prostate Cancer, and Thyroid Cancer......16
Table 15: No. of Cancer Patients Death by Type in the US (2015) - Percentage Share Breakdown for Breast, Colorectal, Lung, Melanoma, and Prostate......17
Table 16: Oncology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Solid Tumor and Others......18
Table 17: No. of Cancer Patients by Type in the US (2015) - Percentage Market Share Breakdown for Colorectal Cancer (CRC), Melanoma, Non-Squamous Non-Small-Cell Lung Cancer (NSCLC), Ovarian, Prostate, Renal Cell Carcinoma (RCC), and Squamous Non-Small-Cell Lung Cancer (NSCLC)......19
Bladder Cancer......20
Table 18: No. of Bladder Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Invasive Patients, and Non-Invasive Patients......20
Breast Cancer......21
Table 19: Breast Cancer Diagnoses by Hospital Type in the US (2015) - Percentage Share Breakdown by Volume for Community, Comprehensive, Teaching and Research, and Others......21
Cervical Cancer......22
Table 20: Cervical Cancer Market by HPV Type in England (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 33, HPV 45, and Others......22
Table 21: Cervical Cancer Market by HPV Type in Europe (2015) - Percentage Share Breakdown by Value for HPV 16, HPV 18, HPV 31, HPV 33, and Others......23
Colorectal Cancer......24
Table 22: No. of Colorectal Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......24
Hematological Cancer......25
Table 23: Hematological Cancer by Category Worldwide (2015) - Percentage Market Share Breakdown by Value Sales for Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), and Non-Hodgkin’s Lymphoma (NHL)......25
Invasive Breast Cancer......26
Table 24: No. of Invasive Breast Cancer Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......26
Table 25: No. of Invasive Breast Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I and Stage II-III......27
Primary Liver Cancer......28
Table 26: No. of Primary Liver Cancer Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......28
Skin Cancer......29
Table 27: Skin Cancer by Type Worldwide (2015) - Percentage Market Share Breakdown by Volume for Basal Cell Carcinomas, Melanoma, and Squamous Cell Carcinomas......29
Cancer in Stage 3/4......30
Table 28: New Patients with Cancer in Stage 3/4 by Site in the US (2015) - Percentage Market Share Breakdown by Volume for Colorectal, Lung and Bronchus, Pancreas and Others......30
Solid Cancer Tumor Patients......31
Table 29: No. of Solid Cancer Tumor Patients by Type Worldwide (2015) - Percentage Share Breakdown for Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, and Prostate Cancer......31
Cancer-Associated Mucositis......32
Table 30: Cancer-Associated Mucositis Market by Activity Worldwide (2015) - Percentage Share Breakdown by Value for Breast, Colorectal, Head and Neck, Non-Small Cell Lung cancer and Others......32
Cancer Drugs......33
Table 31: Oncology Drug Market by Region Worldwide (2015) - Percentage Share Breakdown by Value for European Union Five, Japan, US and Others......33
Chronic Lymphocytic Leukemia (CLL)......34
Table 32: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......34
Table 33: No. of Chronic Lymphocytic Leukemia (CLL) (1L) Patients by Category Worldwide (2015) - Percentage Market Share Breakdown for Imbruvica PCYC, Rituxan, Gazyva ROG, and Others......35
Table 34: No. of Chronic Lymphocytic Leukemia (CLL) (R/R) Patients by Category in European Union (2015) - Percentage Market Share Breakdown for Rituxan, Gazyva, and Others......36
Chronic Myelogenous Leukemia (CML)......37
Table 35: Chronic Myelogenous Leukemia (CML) Market by Region Worldwide (2015) - Percentage Share Breakdown by Value Sales for Asia-Pacific, Canada, European Union, Japan, USA, and Others......37
Cutaneous Melanoma......38
Table 36: No. of Cutaneous Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......38
Ocular Melanoma......39
Table 37: No. of Ocular Melanoma Patients by Region Worldwide (2015) - Percentage Market Share Breakdown for Asia, Australia, Europe, and US......39
Female Mortality......40
Table 38: Female Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Lung, Breast, Colon, Rectum and Anus, Intestine, Liver, and Others......40
Male Mortality......41
Table 39: Male Mortality by Cancer Type in China (2015) - Percentage Market Share Breakdown by Volume for Colon, Colon, Rectum and Anus, Intestine, Liver, Lung, and Others......41
Nausea and Vomiting Associated With Cancer Chemotherapy......42
Table 40: Nausea and Vomiting Associated With Cancer Chemotherapy Market by Drug in European Union (2015) - Percentage Share Breakdown by Value for Aprepitant (Emend), Netupitant (Akynzeo), and Rolapitant (Varubi)......42
Multiple Myeloma......43
Table 41: Multiple Myeloma by Age Group Worldwide (2015) - Percentage Share Breakdown by No. of New Cases for 45-54, 55-64, 65-74, 75-84, >84, and Others......43
Table 42: Multiple Myeloma Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for Kyprolis AMGN, Pomalyst CELG, Revlimid CELG, Thalomid CELG, and Velcade TKD/JNJ......44
Non Small Cell Lung Cancer Patients......45
Table 43: No. of Non Small Cell Lung Cancer Patients by Category in the US (2015) - Percentage Market Share Breakdown for Stage I, Stage II-III, Stage III-IV, and Undiagnozed......45
Primary Brain Tumors......46
Table 44: Primary Brain Tumors by Type in the US (2015) - Percentage Market Share Breakdown for Anaplastic Astrocytoma, Glioblastoma, Oligodendroma, and Others......46
Hepatitis C......47
Table 45: Hepatitis C Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Immuno Modulator, Polymerase Inhibitor, Protease Inhibitors, and Others (Includes Ribavirin)......47
Table 46: Hepatitis C Market by Genotype Worldwide (2015) - Percentage Share Breakdown by Value for Genotype 1, Genotype 2 and Others......48
Table 47: Hepatitis C Virus Market by Category Worldwide (2015) - Percentage Share Breakdown by Value for Immuno-Modulator, Polymerase Inhibitor, Protease Inhibitors, Ribavirin, and Others......49
Table 48: Hepatitis C Virus Market by Patient Conditions in Europe (2015) - Percentage Share Breakdown by Value for Diagnosed, Prevalence, Under Care and Others......50
Table 49: No. of Hepatitis C Virus (HCV) Patients by Category in European Union (EU) (2015) - Percentage Market Share Breakdown for GT1, and Non-GT1......51
Table 50: Hepatitis C Virus Market by Patient Conditions in the US (2015) - Percentage Share Breakdown by Value for Diagnosed, Prevalence, Under Care and Others......52
Table 51: Health Insurance for Hepatitis C Virus (HCV) by Type in the US (2015) - Percentage Market Share Breakdown by Value for Commercial, Dual (Medicare and Medicaid), Medicaid, Medicare (Non- Dual), Prison, Uninsured, and Veteran Affairs......53
Table 52: No. of Hepatitis C Virus (HCV) Patients by Category in the US (2015) - Percentage Market Share Breakdown for GT1 HCV, GT2/3 HCV, and Others......54
Multiple Sclerosis......55
Table 53: Multiple Sclerosis Disease Occurrence by Type Worldwide (2015) - Percentage Breakdown by Volume for Begin MS, Primary Progressive MS, Relapsing-Remiting MS, and Secondary Progressive MS......55
Table 54: Multiple Sclerosis Patient Care Expenditure by Category Worldwide (2015) - Percentage Breakdown by Value for Adaptations, Ambulatory Care, Disease Modifying Drugs, Early Retirement, Hospital Inpatient Care, Informal Care, Prescription and OTC Drugs, Services, Sick-leave and Redused Working Time, and Tests......56
Table 55: Relapsing-Remitting Multiple Sclerosis (RRMS) Market by Region Worldwide (2015) - Percentage Share Breakdown by Volume for European Union (EU), US, Rest of World (RoW)......57
Table 56: No. of Tcelna (Imilecleucel-T) Secondary Progressive Multiple Sclerosis Patients by Category in the US (2015) - Percentage Breakdown for Primary Progressive MS Patients, Relapsing-Remitting MS Patients, and Secondary-Progressive MS Patients......58
Cardiovascular......59
Table 57: Cardiovascular Market by Category Worldwide (2015) - Percentage Share Breakdown by Value Sales for ACE Inhibitors, Alpha Blockers, Angiotensin Receptor Blockers, Anti-Arrhythmics, Anti-Thrombotics, Beta Blockers, Calcium Channel Blockers, Cholesterol, GP IIb/IIIa Inhibitors, Vasodilators, and Others......59
Table 58: Cardiology Market by Category in the US (2015) - Percentage Breakdown by Value Sales for ACE Inhibitors, Alpha Blockers, Anti-Arrhythmics, ARB's, Beta Blockers, Calcium Blockers, Cholesterol, Digitalis, Diuretics, Vasodilators, and Others......60
Table 59: Cardiology Market by Segment in the US (2015) - Percentage Share Breakdown by Value for Cardiac Rhythm Management & Congestive Heart Failure Devices, Cardiac Surgery, and Interventional Cardiology......61
Rheumatoid Arthritis......62
Table 60: Rheumatoid Arthritis Market by Product Type Worldwide (2015) - Percentage Share Breakdown by Value Sales for ENBREL, HUMIRA, REMICADE, and Others......62
Cystic Fibrosis (CF)......63
Table 61: Cystic Fibrosis (CF) Patient Population by Region Worldwide (2015) - Percentage Share Breakdown by Value for Australia, Canada, Rest of Europe, United Kingdom and USA......63
Kidney Disease Drugs......64
Table 62: Traditional Chinese Medicine (TCM) Market for Kidney Ailments by Drug in China (2015) - Percentage Share Breakdown by Value Sales for Ambrette Capsule, Haikunshenxi Capsule, Shenyankangfu Tablet, Uremic Clearance Granule, Yinhuamiyangling and Others......64
Table 63: Kidney Disease Market by Drug in the US (2015) - Percentage Share Breakdown by Value Sales for Aranesp and Others......65
Table 64: Dialysis Market by Drug in the US (2015) - Percentage Share Breakdown by Value Sales for Aranesp, EPO alfa/beta biosimilars and Others......66
Table 65: Hemodialysis Market by Drug in the US (2015) - Percentage Share Breakdown by Value Sales for Aranesp, Epogen, and Others......67
Table 66: Chronic Kidney Disease Market by Drug in the US (2015) - Percentage Share Breakdown by Value Sales for Aranesp and Others......68
Table 67: Peritoneal Dialysis Market by Drug in the US (2015) - Percentage Share Breakdown by Value Sales for Aranesp, Epogen, and Others (Includes Mircera)......69
Table 68: New Patients with Kidney Failure by Cause in the US (2015) - Percentage Share Breakdown by Volume for Diabetes, High Blood Pressure and Others......70
Biopharmaceuticals......71
Table 69: Market Shares of Leading Biopharmaceutical Companies Worldwide (2014) - Percentage Breakdown by Volume (Installed Capacity) for Amgen Inc., Biogen Idec, Inc., Bristol-Myers Squibb Company, C.H. Boehringer Sohn AG & Co. KG, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Ltd., Lonza Group Ltd., Pfizer, Inc., Sanofi S.A., and Others......71
Table 70: Market Shares of Leading Biopharmaceutical Companies in the US (2015) - Percentage Market Share Breakdown by Value for Actelion Pharmaceuticals Ltd., Alexion Pharmaceuticals, Inc., Celgene Corporation, Gilead Sciences, Inc., Incyte, Corporation, Isis Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc., and Others......72
Cancer Drugs......73
Table 71: Market Shares of Leading Oncology Product Manufacturers Worldwide (2015) - Percentage Breakdown by Value for Fresenius SE & Co., and Others......73
Table 72: Market Shares of Leading Oncology/Hematology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......74
Table 73: Market Shares of Leading Oncology Drug Manufacturers in China (2015) - Percentage Share Breakdown by Value for Astrazeneca, Jiangsu Hengrui Medicine Co., Ltd., Roche Group and Others......75
Table 74: Anti-Cancer Drugs Market by Product Type in China (2015) - Percentage Share Breakdown by Value for Anastrozole, Capecitabine, Cetuximab, Compound kushen, Docetaxel, Epirubicin, Erlotinib, Gefitinib, Gemcitabine, Goserelin, Interferon α-2a, Interferon α-2b, Irinotecan, Kangai, Lentinan, Letrozole, Oxaliplatin, Paclitaxel, Pemetrexed, Pidotimod, RhG-CSF, RhIL-2, Rituximab, Sorafenib, Sshenqi Fuzheng, Thymopentin, Thymosin a1, Trastuzmmab, Triptorelin, TS-1, and Others......76
Table 75: Anti-Cancer Drugs Market by Type in China (2015) - Percentage Share Breakdown by Value for Alkylating Agents, Antibiotics, Antimetabolites, Hormonal Agents, Immunostimulant, Plant Alkaloids, and Others......77
Breast Cancer Drugs......78
Table 76: Market Shares of Leading Breast Cancer Drugs by Value Sales in China (2014) - Percentage Breakdown for Alkylating Agents, Antimetabolite, Antitumor Antibiotics, Antitumor Antihormone, Antitumor Botanicals, Monoclonal Antibodies, Targeted Small Molecule Agents, and Others......78
Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL)......79
Table 77: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia (CLL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......79
Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL)......80
Table 78: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory (RR) Indolent Non-Hodgkin's Lymphoma (iNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib, Idelalisib and Others......80
Table 79: Market Shares of Leading Drugs for Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma (R/R- aNHL) in the US (2015) - Percentage Share Breakdown by Value for Ibrutinib and Others......81
HBV/HCV Therapeutics......82
Table 80: Market Shares of Leading HBV/HCV Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., and Others......82
Table 81: Market Shares of Leading Hepatitis C Virus (HCV), Hepatitis B Virus (HBV) Drugs Manufacturers by Value Sales Worldwide (2014) - Percentage Breakdown for Bristol-Myers Squibb Co (BMY), GlaxoSmithKline Plc (GSK), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Vertex Pharmaceuticals, Inc. (VRTX), and Others......83
Cardiology Therapeutics......84
Table 82: Market Shares of Leading Cardiology Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for AbbVie, AstraZeneca Plc, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Forest Laboratories, Inc., GlaxoSmithKline Plc, Johnson & Johnson, Merck Ltd., Novartis AG, Pfizer, Inc., Sanofi S.A., and Others......84
Multiple Sclerosis......85
Table 83: Market Shares of Leading Multiple Sclerosis Therapeutic Providers by Value Sales Worldwide (2014) - Percentage Breakdown for Biogen Idec, Novartis AG, Sanofi S.A., and Others......85
Table 84: Market Shares of Leading Drug Brands for Relapsing-Remitting Multiple Sclerosis (RRMS) Worldwide (2015) - Percentage Breakdown by No. of Patients for Avonex, Betaseron, Copaxone, Gilenya, Laquinimod, Rebif, Tysabri, and Others......86
Table 85: Market Shares of Leading Drug Brands for Relapsing-Remitting Multiple Sclerosis (RRMS) Worldwide (2015) - Percentage Breakdown by Value for Avonex, Betaseron, Copaxone, Gilenya, Laquinimod, Rebif, Tysabri, and Others......87